Hikma stock gains after solid half-year figures and dividend increase

Published on 09/15/2026 at 18:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hikma stock closed at GBP 15.44 on the London Stock Exchange on September 11, 2026, 0.85 percent above the prior day. The company reported higher revenue and raised its interim dividend for the first half of 2026, supporting the shares.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma Pharmaceuticals stock (ISIN GB00B128J450) closed at GBP 15.44 on the London Stock Exchange on September 11, 2026, up 0.85 percent from the previous close, giving the company a mid-cap valuation in the UK pharma sector.

Half-year 2026 results underpin Hikma stock

According to Hikma Pharmaceuticals in its latest half-year report for the first six months of 2026, group revenue increased compared with the prior year period, reflecting growth across its injectables and branded businesses.

In the same half-year 2026 report, Hikma also reported a higher core operating profit than in the first half of 2025, indicating that the company converted revenue growth into improved profitability.

Dividend increase and guidance support investor interest

Per the half-year 2026 disclosure from Hikma Pharmaceuticals, the board approved an increased interim dividend versus the payment for the first half of 2025, offering shareholders a tangible benefit from the stronger results.

According to the same half-year 2026 communication from Hikma Pharmaceuticals, management reiterated its full-year guidance, signaling confidence that the company can sustain its revenue and profit trajectory into the remainder of 2026.

Stock valuation and trading context

At the closing price of GBP 15.44 on September 11, 2026, Hikma stock trades at a level that reflects the market's assessment of its improved earnings profile following the first half of 2026, with the recent uptick of 0.85 percent suggesting a constructive reaction to the latest figures.